1. Home
  2. PMEC vs GRDX Comparison

PMEC vs GRDX Comparison

Compare PMEC & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Primech Holdings Ltd.

PMEC

Primech Holdings Ltd.

HOLD

Current Price

$0.55

Market Cap

30.4M

Sector

N/A

ML Signal

HOLD

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

N/A

Current Price

$3.91

Market Cap

28.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PMEC
GRDX
Founded
1984
N/A
Country
Singapore
United Kingdom
Employees
N/A
2
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.4M
28.6M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
PMEC
GRDX
Price
$0.55
$3.91
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
151.0K
68.4K
Earning Date
07-24-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$1.87
52 Week High
$2.44
$6.93

Technical Indicators

Market Signals
Indicator
PMEC
GRDX
Relative Strength Index (RSI) 38.43 39.61
Support Level $0.52 $2.01
Resistance Level $0.80 $5.30
Average True Range (ATR) 0.05 0.42
MACD -0.01 -0.09
Stochastic Oscillator 22.90 8.78

Price Performance

Historical Comparison
PMEC
GRDX

About PMEC Primech Holdings Ltd.

Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: